Explore

TrendlineTrendline
Abbisko Therapeutics Reports Positive Phase 2 Results for Lavengratinib in Achondroplasia Treatment

Abbisko Therapeutics Reports Positive Phase 2 Results for Lavengratinib in Achondroplasia Treatment

Abbisko Therapeutics Reports Positive Phase 2 Results for Lavengratinib in Achondroplasia Treatment
Rapid ReadRapid Read
Wearable Technology Advances in Parkinson's Disease Treatment for Freezing of Gait

Wearable Technology Advances in Parkinson's Disease Treatment for Freezing of Gait

Advances in wearable technology and computational classification are significantly improving the evaluation and treatment of Freezing of Gait (FoG) in Parkinson's disease (PD). Wearable inertial measurement units (wIMUs), which combine accelerometers, magnetometers, and gyroscopes, are now extensively used for real-world detection of FoG. These devices can be worn on various body parts, including the ankle, thigh, torso, lumbar area, and waist, to characterize movements and identify FoG episodes using pre-defined thresholds or algorithmic classifiers. Publicly available datasets from gait laboratories are being utilized to train these classifiers. Beyond wIMUs, other devices like ambulatory EEGs and ECGs are being explored to detect physiological markers preceding FoG episodes. Augmented and mixed reality devices are also collecting contextual information to identify triggers, while virtual reality paradigms simulate FoG triggers for systematic assessments. These technological advancements aim to provide m...
ReutersReuters
Grail rallies as FDA staff flags no major concerns for multi-cancer test

Grail rallies as FDA staff flags no major concerns for multi-cancer test

By Christy Santhosh and Padmanabhan Ananthan Sept 21 (Reuters) - The US FDA's staff reviewers did not raise major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers, sending the company's shares soaring 35% on Monday.
Rapid ReadRapid Read
MaaT Pharma Schedules Pre-IND Meeting with FDA for MaaT034 in Solid Tumors

MaaT Pharma Schedules Pre-IND Meeting with FDA for MaaT034 in Solid Tumors

MaaT Pharma, a clinical-stage biotechnology company, has scheduled a Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for October 2026. This meeting will focus on Chemistry, Manufacturing, and Controls (CMC) for MaaT034, a novel Microbiome Ecosystem Therapy (MET-C) candidate. MaaT034 is designed to be evaluated in combination with PD-(L)1 inhibitors for advanced solid tumors, including second-line advanced non-small cell lung cancer (NSCLC) and refractory advanced melanoma. The company aims to initiate a First-in-Human study in late 2027, pending regulatory clearance and funding. MaaT034 is the first candidate from MaaT Pharma's MET-C platform, which utilizes artificial intelligence and co-culture technology to produce functionally selected microbial ecosystems.
Rapid ReadRapid Read
Beacon Therapeutics Prepares FDA Filing for XLRP Gene Therapy After Positive Phase 3 Results

Beacon Therapeutics Prepares FDA Filing for XLRP Gene Therapy After Positive Phase 3 Results

Beacon Therapeutics is preparing to submit a rolling Biologics License Application (BLA) to the FDA later this year for its gene therapy, laruparetigene zovaparvovec (laru-zova), which treats X-linked retinitis pigmentosa (XLRP). This decision follows positive results from the pivotal Phase 2/3 VISTA trial, where laru-zova met its primary endpoint with statistical significance. The trial demonstrated a significant improvement in low luminance visual acuity (LLVA) responder rates at 12 months compared to an untreated control group. Specifically, 31% of XLRP patients receiving a high dose and 24.1% receiving a low dose achieved an improvement of 15 letters or more on an eye chart, with no responders in the control group. The gene therapy also exhibited a favorable safety and tolerability profile consistent with previous studies.
Rapid ReadRapid Read
Virtual Healthcare Market Projected for Significant Growth with 12.9% CAGR by 2033

Virtual Healthcare Market Projected for Significant Growth with 12.9% CAGR by 2033

The virtual healthcare market is experiencing rapid expansion, driven by increasing consumer demand for convenient and cost-efficient care. Projections indicate a compound annual growth rate (CAGR) of 12.9% from 2026 to 2033. This growth is fueled by the integration of wearable health technology, the rise of virtual-first health plans, and the stabilization of reimbursement parity with in-person visits. Key players like Teladoc Health, American Well (Amwell), and MDLIVE are leading this sector by offering comprehensive platforms that include teleconsultations, remote patient monitoring, and integrated mental health services. Advancements in 5G connectivity, edge computing, and generative AI are enhancing diagnostic accuracy and platform interoperability, further supporting this market expansion. While the FDA’s digital health precertification program is accelerating software approvals, the upcoming expiration of COVID-era telehealth waivers in the U.S. introduces some reimbursement uncertainty. Despite the...
Rapid ReadRapid Read
Mercy BioAnalytics Receives FDA Approval for Pivotal Ovarian Cancer Screening Study

Mercy BioAnalytics Receives FDA Approval for Pivotal Ovarian Cancer Screening Study

Mercy BioAnalytics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for the Evident™ Ovarian Cancer Screening Test. This approval permits Mercy BioAnalytics to initiate its pivotal SOARA Clinical Validation Study. The study is a prospective clinical trial designed to assess the safety of the Evident test when used for ovarian cancer screening in women at average risk, contingent upon Institutional Review Board (IRB) approval. The company aims for this study to support its ongoing clinical and regulatory efforts for the Evident Ovarian Cancer Screening Test. The Evident test utilizes Mercy's patented Mercy Halo™ liquid biopsy platform, which identifies cancer-associated signatures from extracellular vesicles and particles in blood. This FDA approval marks a significant step in advancing the test through the regulatory review process, as stated by Dawn Mattoon, Ph.D., Chief Executive Officer of Mercy BioAnalytics.
Rapid ReadRapid Read
New Fabrication Techniques Advance Wearable Organic Electronics for Enhanced Bioelectronic Devices

New Fabrication Techniques Advance Wearable Organic Electronics for Enhanced Bioelectronic Devices

Researchers are developing new fabrication techniques for organic mixed ionic-electronic conductors (OMIECs) to advance wearable technology. OMIECs are crucial for bioelectronic devices because they can transport both ionic and electronic charges, bridging the gap between biological systems (which primarily use ions for signal transmission) and conventional electronics (which rely on electrons). These new techniques, particularly direct photopatterning, address challenges in manufacturing OMIECs, such as consistency, scalability, and the integration of multiple materials into a single device. Direct photopatterning uses ultraviolet (UV) light to define structures in a material, making it insoluble in exposed areas while unexposed areas can be removed with a solvent. This method is compatible with existing manufacturing processes and allows for the creation of reproducible and scalable device structures, as well as the patterning of different OMIEC materials on the same substrate without compromising perfor...
Rapid ReadRapid Read
FDA Moves to Reduce Animal Testing Requirements for Drug Approval

FDA Moves to Reduce Animal Testing Requirements for Drug Approval

The U.S. Food and Drug Administration (FDA) has issued a direct final rule aimed at removing outdated references to animal testing in its drug and biologics regulations. This action is a significant step towards encouraging drug companies to utilize cutting-edge non-animal testing methods. Despite the FDA's public commitment to advancing non-animal test methods, existing regulations have often led companies to believe that animal testing is a mandatory requirement for drug approval. The new rule, which could become effective as early as February 4, 2027, directly responds to a 2024 legal petition filed by Humane World for Animals and Humane World Action Fund. These organizations advocated for the FDA to clarify that animal testing is not legally required. This initiative aligns with the FDA's stated goal of making animal tests "the exception rather than the norm" for preclinical safety and toxicity testing within the next three to five years.
Rapid ReadRapid Read
Senator Roger Wicker Anticipates Further Breakthroughs in Duchenne Muscular Dystrophy Research

Senator Roger Wicker Anticipates Further Breakthroughs in Duchenne Muscular Dystrophy Research

Senator Roger Wicker (R-MS) has expressed optimism about continued advancements in the treatment and potential cure for Duchenne Muscular Dystrophy (DMD). This year marks the 25th anniversary of the Muscular Dystrophy Community Assistance, Research, and Education (MD CARE) Act, legislation Senator Wicker co-authored in 2001. This act was instrumental in unlocking research funding for DMD. Over the past 25 years, significant progress has been made, transforming the prognosis for many DMD patients, who now often live into adulthood, a stark contrast to the limited life expectancy in the early 2000s. Recent efforts include updating the MD CARE Act in 2014 to include adult patient research and successfully advocating for the inclusion of Duchenne on the Recommended Uniform Screening Panel (RUSP) by the Department of Health and Human Services (HHS) last December, which encourages states to test newborns for the condition.
Rapid ReadRapid Read
Abbisko Therapeutics Reports Positive Phase 2 Results for Lavengratinib in Achondroplasia Treatment

Abbisko Therapeutics Reports Positive Phase 2 Results for Lavengratinib in Achondroplasia Treatment

Abbisko Therapeutics has announced positive preliminary efficacy results from its Phase II clinical study of lavengratinib (ABSK061), a selective orally available small-molecule FGFR2/3 inhibitor, for children with achondroplasia (ACH). In the initial and lowest dose cohort (0.064mg/kg QD), children aged 6 years and older with ACH who received lavengratinib for 27 weeks showed a mean increase of +2.4 cm/year in annualized height velocity (AHV) from baseline, achieving a 100% responder rate. The drug was well-tolerated, with no observed FGFR1 or FGFR2-associated adverse events. The ABSK061-202 study is a Phase II, multicenter, open-label, dose-escalation study evaluating the safety and efficacy of lavengratinib in children aged 3 to 12 years with ACH, with a planned treatment duration of 78 weeks. Preliminary safety evaluations for the first three dose cohorts have been successfully completed without identifying any safety concerns.
Rapid ReadRapid Read
Rep. John Carter Supports Bipartisan ASAP Act for Medicare Coverage of Alzheimer's Blood Tests

Rep. John Carter Supports Bipartisan ASAP Act for Medicare Coverage of Alzheimer's Blood Tests

Rep. John Carter is advocating for the bipartisan Alzheimer’s Screening and Prevention (ASAP) Act, which aims to enable Medicare coverage for FDA-approved blood tests designed to detect Alzheimer’s biomarkers. Currently, Medicare regulations prohibit coverage for any dementia screening test for individuals without symptoms, creating a significant barrier to early detection. The ASAP Act seeks to rectify this legal impediment, offering a more scalable and accessible diagnostic approach compared to previous methods. This legislative effort is highlighted by Stephenie Evans, a former caregiver from Belton, Texas, who emphasizes the critical difference early detection can make for families affected by Alzheimer's. Her personal experience with her grandmother, who lived with Alzheimer's for a decade, underscores the potential for earlier diagnoses to improve quality of life and allow families more time to prepare for the future. The initiative aligns with global efforts to raise awareness and challenge the stig...